HST Global, Inc. (HSTC)
USD 0.83
(0.0%)
USD 0.83
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 593.59 Thousand USD | 33.08% |
| 2022 | 446.04 Thousand USD | 48.18% |
| 2021 | 301 Thousand USD | 96.63% |
| 2020 | 153.08 Thousand USD | 2742.77% |
| 2019 | 5385.00 USD | -99.84% |
| 2018 | 3.37 Million USD | 5.58% |
| 2017 | 3.19 Million USD | 5.45% |
| 2016 | 3.02 Million USD | 6.07% |
| 2015 | 2.85 Million USD | 7.37% |
| 2014 | 2.65 Million USD | 7.46% |
| 2013 | 2.47 Million USD | 8.4% |
| 2012 | 2.28 Million USD | 19.77% |
| 2011 | 1.9 Million USD | 3.24% |
| 2010 | 1.84 Million USD | 38.28% |
| 2009 | 1.33 Million USD | 231.36% |
| 2008 | 402.87 Thousand USD | -78.23% |
| 2007 | 1.85 Million USD | -90.0% |
| 2006 | 18.5 Million USD | 1982.04% |
| 2005 | 888.74 Thousand USD | 112.94% |
| 2004 | 417.36 Thousand USD | -32.06% |
| 2003 | 614.33 Thousand USD | -57.52% |
| 2002 | 1.44 Million USD | -19.38% |
| 2001 | 1.79 Million USD | -11.63% |
| 2000 | 2.03 Million USD | 1094.12% |
| 1999 | 170 Thousand USD | -91.19% |
| 1998 | 1.93 Million USD | -52.23% |
| 1997 | 4.04 Million USD | 3.59% |
| 1996 | 3.9 Million USD | -31.58% |
| 1995 | 5.7 Million USD | 14.0% |
| 1994 | 5 Million USD | 2.04% |
| 1993 | 4.9 Million USD | 113.04% |
| 1992 | 2.3 Million USD | -17.86% |
| 1991 | 2.8 Million USD | 133.33% |
| 1990 | 1.2 Million USD | 9.09% |
| 1989 | 1.1 Million USD | 57.14% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 23.03 Thousand USD | -96.33% |
| 2024 Q1 | 627.08 Thousand USD | 5.64% |
| 2023 Q3 | 557.16 Thousand USD | 6.79% |
| 2023 FY | 593.59 Thousand USD | 33.08% |
| 2023 Q2 | 521.75 Thousand USD | 7.52% |
| 2023 Q4 | 593.59 Thousand USD | 6.54% |
| 2023 Q1 | 485.25 Thousand USD | 8.79% |
| 2022 Q1 | 339.12 Thousand USD | 12.66% |
| 2022 Q4 | 446.04 Thousand USD | 8.68% |
| 2022 Q3 | 410.42 Thousand USD | 9.48% |
| 2022 Q2 | 374.87 Thousand USD | 10.54% |
| 2022 FY | 446.04 Thousand USD | 48.18% |
| 2021 Q1 | 191.16 Thousand USD | 24.88% |
| 2021 Q2 | 231.16 Thousand USD | 20.92% |
| 2021 FY | 301 Thousand USD | 96.63% |
| 2021 Q3 | 265.9 Thousand USD | 15.03% |
| 2021 Q4 | 301 Thousand USD | 13.2% |
| 2020 FY | 153.08 Thousand USD | 2742.77% |
| 2020 Q4 | 153.08 Thousand USD | 29.76% |
| 2020 Q1 | 38.26 Thousand USD | 610.57% |
| 2020 Q2 | 83.76 Thousand USD | 118.91% |
| 2020 Q3 | 117.97 Thousand USD | 40.84% |
| 2019 FY | 5385.00 USD | -99.84% |
| 2019 Q1 | 3.41 Million USD | 1.34% |
| 2019 Q2 | 964.9 Thousand USD | -71.75% |
| 2019 Q3 | - USD | -100.0% |
| 2019 Q4 | 5385.00 USD | 0.0% |
| 2018 Q4 | 3.37 Million USD | 1.31% |
| 2018 FY | 3.37 Million USD | 5.58% |
| 2018 Q1 | 3.23 Million USD | 1.46% |
| 2018 Q2 | 3.28 Million USD | 1.37% |
| 2018 Q3 | 3.32 Million USD | 1.33% |
| 2017 Q1 | 3.08 Million USD | 2.05% |
| 2017 Q2 | 3.13 Million USD | 1.41% |
| 2017 Q3 | 3.14 Million USD | 0.52% |
| 2017 Q4 | 3.19 Million USD | 1.37% |
| 2017 FY | 3.19 Million USD | 5.45% |
| 2016 Q4 | 3.02 Million USD | 1.46% |
| 2016 Q2 | 2.94 Million USD | 1.55% |
| 2016 FY | 3.02 Million USD | 6.07% |
| 2016 Q1 | 2.89 Million USD | 1.48% |
| 2016 Q3 | 2.98 Million USD | 1.44% |
| 2015 Q1 | 2.72 Million USD | 2.3% |
| 2015 Q4 | 2.85 Million USD | 1.71% |
| 2015 FY | 2.85 Million USD | 7.37% |
| 2015 Q3 | 2.8 Million USD | 1.5% |
| 2015 Q2 | 2.76 Million USD | 1.66% |
| 2014 Q4 | 2.65 Million USD | 1.69% |
| 2014 Q1 | 2.52 Million USD | 1.9% |
| 2014 FY | 2.65 Million USD | 7.46% |
| 2014 Q3 | 2.61 Million USD | 1.83% |
| 2014 Q2 | 2.56 Million USD | 1.84% |
| 2013 Q3 | 2.43 Million USD | 1.93% |
| 2013 FY | 2.47 Million USD | 8.4% |
| 2013 Q4 | 2.47 Million USD | 1.7% |
| 2013 Q2 | 2.38 Million USD | 2.78% |
| 2013 Q1 | 2.32 Million USD | 1.74% |
| 2012 Q1 | 1.99 Million USD | 4.5% |
| 2012 Q4 | 2.28 Million USD | 4.08% |
| 2012 Q2 | 2.1 Million USD | 5.51% |
| 2012 FY | 2.28 Million USD | 19.77% |
| 2012 Q3 | 2.19 Million USD | 4.36% |
| 2011 FY | 1.9 Million USD | 3.24% |
| 2011 Q1 | 1.61 Million USD | -12.69% |
| 2011 Q2 | 1.71 Million USD | 6.11% |
| 2011 Q3 | 1.79 Million USD | 4.79% |
| 2011 Q4 | 1.9 Million USD | 6.34% |
| 2010 Q4 | 1.84 Million USD | 10.08% |
| 2010 FY | 1.84 Million USD | 38.28% |
| 2010 Q3 | 1.67 Million USD | 10.17% |
| 2010 Q2 | 1.52 Million USD | 13.68% |
| 2010 Q1 | 1.33 Million USD | 0.3% |
| 2009 Q2 | 652.36 Thousand USD | 4.22% |
| 2009 Q4 | 1.33 Million USD | 38.56% |
| 2009 FY | 1.33 Million USD | 231.36% |
| 2009 Q1 | 625.96 Thousand USD | 55.38% |
| 2009 Q3 | 963.46 Thousand USD | 47.69% |
| 2008 Q4 | 402.87 Thousand USD | 136.96% |
| 2008 FY | 402.87 Thousand USD | -78.23% |
| 2008 Q1 | 1.92 Million USD | 3.96% |
| 2008 Q2 | 1.19 Million USD | -37.74% |
| 2008 Q3 | 170.02 Thousand USD | -85.8% |
| 2007 Q2 | 1.7 Million USD | -88.76% |
| 2007 Q1 | 15.18 Million USD | -17.93% |
| 2007 FY | 1.85 Million USD | -90.0% |
| 2007 Q4 | 1.85 Million USD | 2.45% |
| 2007 Q3 | 1.8 Million USD | 5.78% |
| 2006 Q2 | 18.44 Million USD | 1265.22% |
| 2006 Q1 | 1.35 Million USD | 52.01% |
| 2006 Q4 | 18.5 Million USD | -4.11% |
| 2006 FY | 18.5 Million USD | 1982.04% |
| 2006 Q3 | 19.29 Million USD | 4.63% |
| 2005 Q3 | - USD | -100.0% |
| 2005 FY | 888.74 Thousand USD | 112.94% |
| 2005 Q1 | 442.88 Thousand USD | 6.11% |
| 2005 Q2 | 457.4 Thousand USD | 3.28% |
| 2005 Q4 | 888.74 Thousand USD | 0.0% |
| 2004 Q4 | 417.36 Thousand USD | -35.8% |
| 2004 Q2 | 625.35 Thousand USD | 1.91% |
| 2004 Q1 | 613.61 Thousand USD | -0.12% |
| 2004 Q3 | 650.12 Thousand USD | 3.96% |
| 2004 FY | 417.36 Thousand USD | -32.06% |
| 2003 Q4 | 614.33 Thousand USD | 3.34% |
| 2003 Q1 | 1.31 Million USD | -9.21% |
| 2003 FY | 614.33 Thousand USD | -57.52% |
| 2003 Q3 | 594.44 Thousand USD | -55.24% |
| 2003 Q2 | 1.32 Million USD | 1.14% |
| 2002 FY | 1.44 Million USD | -19.38% |
| 2002 Q1 | 1.79 Million USD | 0.05% |
| 2002 Q2 | 1.91 Million USD | 6.66% |
| 2002 Q3 | 2.1 Million USD | 10.25% |
| 2002 Q4 | 1.44 Million USD | -31.33% |
| 2001 Q4 | 1.79 Million USD | -13.94% |
| 2001 FY | 1.79 Million USD | -11.63% |
| 2001 Q1 | 2.06 Million USD | 1.48% |
| 2001 Q2 | 2.07 Million USD | 0.49% |
| 2001 Q3 | 2.08 Million USD | 0.48% |
| 2000 Q1 | 200 Thousand USD | 17.65% |
| 2000 Q4 | 2.03 Million USD | 109.28% |
| 2000 Q3 | 970 Thousand USD | 115.56% |
| 2000 Q2 | 450 Thousand USD | 125.0% |
| 2000 FY | 2.03 Million USD | 1094.12% |
| 1999 Q4 | 170 Thousand USD | 41.67% |
| 1999 Q3 | 120 Thousand USD | -47.83% |
| 1999 FY | 170 Thousand USD | -91.19% |
| 1999 Q1 | 1.95 Million USD | 1.04% |
| 1999 Q2 | 230 Thousand USD | -88.21% |
| 1998 Q2 | 2.32 Million USD | -43.41% |
| 1998 Q3 | 2.23 Million USD | -3.88% |
| 1998 Q1 | 4.1 Million USD | 1.49% |
| 1998 Q4 | 1.93 Million USD | -13.45% |
| 1998 FY | 1.93 Million USD | -52.23% |
| 1997 Q2 | 4.18 Million USD | -12.92% |
| 1997 Q3 | 4.23 Million USD | 1.2% |
| 1997 Q4 | 4.04 Million USD | -4.49% |
| 1997 FY | 4.04 Million USD | 3.59% |
| 1997 Q1 | 4.8 Million USD | 23.08% |
| 1996 FY | 3.9 Million USD | -31.58% |
| 1996 Q1 | 5.7 Million USD | 0.0% |
| 1996 Q2 | 5.5 Million USD | -3.51% |
| 1996 Q3 | 3.5 Million USD | -36.36% |
| 1996 Q4 | 3.9 Million USD | 11.43% |
| 1995 Q4 | 5.7 Million USD | 0.0% |
| 1995 Q1 | 5 Million USD | 0.0% |
| 1995 Q2 | 5 Million USD | 0.0% |
| 1995 Q3 | 5.7 Million USD | 14.0% |
| 1995 FY | 5.7 Million USD | 14.0% |
| 1994 Q4 | 5 Million USD | -1.57% |
| 1994 Q1 | 5.4 Million USD | 10.2% |
| 1994 Q2 | 5.6 Million USD | 3.7% |
| 1994 Q3 | 5.08 Million USD | -9.29% |
| 1994 FY | 5 Million USD | 2.04% |
| 1993 Q1 | 2.1 Million USD | -8.7% |
| 1993 Q2 | 2.1 Million USD | 0.0% |
| 1993 FY | 4.9 Million USD | 113.04% |
| 1993 Q3 | 2.4 Million USD | 14.29% |
| 1993 Q4 | 4.9 Million USD | 104.17% |
| 1992 FY | 2.3 Million USD | -17.86% |
| 1992 Q1 | 2.6 Million USD | -7.14% |
| 1992 Q2 | 2.3 Million USD | -11.54% |
| 1992 Q3 | 2.2 Million USD | -4.35% |
| 1992 Q4 | 2.3 Million USD | 4.55% |
| 1991 Q2 | 1.1 Million USD | 0.0% |
| 1991 Q4 | 2.8 Million USD | 86.67% |
| 1991 FY | 2.8 Million USD | 133.33% |
| 1991 Q1 | 1.1 Million USD | -8.33% |
| 1991 Q3 | 1.5 Million USD | 36.36% |
| 1990 Q3 | 1.3 Million USD | 0.0% |
| 1990 FY | 1.2 Million USD | 9.09% |
| 1990 Q4 | 1.2 Million USD | -7.69% |
| 1990 Q1 | 1.5 Million USD | 36.36% |
| 1990 Q2 | 1.3 Million USD | -13.33% |
| 1989 Q2 | 1.1 Million USD | 0.0% |
| 1989 Q4 | 1.1 Million USD | 0.0% |
| 1989 FY | 1.1 Million USD | 57.14% |
| 1989 Q3 | 1.1 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -2063.792% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 93.729% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.181% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 26.608% |
| Rebus Holdings, Inc. | 5.24 Million USD | 88.676% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 98.994% |
| Qrons Inc. | 1.48 Million USD | 60.127% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 51.591% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.208% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -1228.067% |
| Skye Bioscience, Inc. | 14.07 Million USD | 95.782% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 98.886% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 93.805% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -40.806% |
| SQZ Biotechnologies Company | 50.03 Million USD | 98.814% |
| Intellipharmaceutics International Inc. | 12 Million USD | 95.057% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 84.588% |
| Mesoblast Limited | 188.44 Million USD | 99.685% |
| Marizyme, Inc. | 26.67 Million USD | 97.775% |
| Genus plc | 485 Million USD | 99.878% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 89.84% |
| Pharming Group N.V. | 244.07 Million USD | 99.757% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 70.47% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 76.41% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 84.379% |
| ContraFect Corporation | 32.53 Million USD | 98.175% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 70.04% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 84.492% |
| IMV Inc. | 37.93 Million USD | 98.435% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 94.96% |
| MultiCell Technologies, Inc. | 1617.67 USD | -36594.32% |
| ONE Bio Corp. | 27.49 Million USD | 97.841% |
| Accustem Sciences Inc. | 1.07 Million USD | 44.999% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.233% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 71.935% |
| Q BioMed Inc. | 8.13 Million USD | 92.701% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.284% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 88.465% |
| Biomind Labs Inc. | 1.49 Million USD | 60.39% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.5% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 93.435% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 96.775% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 58.602% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -317.744% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -195.15% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 89.669% |
| GB Sciences, Inc. | 5.41 Million USD | 89.043% |
| Alpha Cognition Inc. | 7.16 Million USD | 91.715% |
| CSL Limited | 18.62 Billion USD | 99.997% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 52.859% |
| Halberd Corporation | 728.71 Thousand USD | 18.543% |
| Enzolytics Inc. | 365.26 Million USD | 99.837% |
| Agentix Corp. | 2.51 Million USD | 76.356% |
| Resverlogix Corp. | 67.39 Million USD | 99.119% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 29.227% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.867% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 65.368% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 97.601% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 95.013% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 83.804% |
| AVAX Technologies, Inc. | 3.99 Million USD | 85.137% |
| Zenith Capital Corp. | 27.56 Thousand USD | -2053.118% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.955% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -148.725% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 84.104% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 12.814% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 78.109% |
| Kadimastem Ltd | 3.5 Million USD | 83.064% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -786.9% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 98.819% |
| BioStem Technologies, Inc. | 15.9 Million USD | 96.268% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -27.737% |
| LadRx Corporation | 2.2 Million USD | 73.025% |
| Cell Source, Inc. | 15.8 Million USD | 96.245% |
| Regen BioPharma, Inc. | 5.45 Million USD | 89.124% |
| Regen BioPharma, Inc. | 5.45 Million USD | 89.124% |
| NovAccess Global Inc. | 7.86 Million USD | 92.449% |
| Affymax, Inc. | 8.87 Million USD | 93.309% |
| Itoco Inc. | 1.65 Million USD | 64.093% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 71.066% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 90.187% |
| Mobile Lads Corp. | 1.31 Million USD | 54.808% |
| CytoDyn Inc. | 127.89 Million USD | 99.536% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -1320.113% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 62.104% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 94.626% |
| SYBLEU INC | 681.41 Thousand USD | 12.888% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 90.272% |
| International Stem Cell Corporation | 5.27 Million USD | 88.751% |
| Bioxytran, Inc. | 3.24 Million USD | 81.733% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 5.148% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 87.144% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 98.552% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 97.334% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 70.692% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 89.164% |
| Neutra Corp. | 973.52 Thousand USD | 39.027% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 97.954% |
| PureTech Health plc | 125.58 Million USD | 99.527% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 84.201% |
| IXICO plc | 1.9 Million USD | 68.763% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 97.109% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.426% |
| CSL Limited | 18.62 Billion USD | 99.997% |
| Cellectis S.A. | 249.36 Million USD | 99.762% |